Gavi Summit Raises US $2.4 Billion More For COVAX Global Vaccine Facility & 54 Million More COVID Vaccine Doses 02/06/2021 Raisa Santos The WHO-sponsored COVAX facility raised another US $2.4 billion on Wednesday from donors to fund more COVID vaccines for low- and middle-income countries – exceeding their total funding target and bringing the total pledged to the COVAX AMC to US $9.6 billion, following a GAVI COVAX AMC Summit “One World Protected” virtual event. But the […] Continue reading -> China Sidesteps COVAX Vaccine Donations; Africa Highlights Pandemic Fallout on Health Systems & Societies 27/05/2021 Paul Adepoju China told the World Health Assembly on Wednesday it will continue to support developing countries’ access to affordable COVID-19 vaccines – but it stopped short of any commitment to supplying its recently-approved Sinopharm vaccine to the WHO co-sponsored Global COVAX vaccine facility. WHO officials had said they hoped China would join the COVAX facility, following […] Continue reading -> Gavi Makes Deal With J&J on COVID-19 Vaccines; WHO Says COVID-19 Deaths Could Be 2-3 Times Higher Than 3.2 Million Reported 21/05/2021 Kerry Cullinan Johnson & Johnson will supply COVAX 200 million of its single-dose COVID-19 vaccines by the end of the year, according to a statement on Friday by Gavi, the Vaccine Alliance, announcing the advance purchase agreement. The vaccine will be available to both COVAX members who buy their own vaccines and the COVAX AMC members. “Today’s […] Continue reading -> Pandemic Treaty & Other New COVID Initiatives Grab Center Stage At World Health Assembly 20/05/2021 Pokuaa Oduro-Bonsrah Conquering the COVID-19 pandemic will inevitably be the main topic for discussion at the impending 74th session of the World Health Assembly, which begins Monday, 24 May. Global health experts weighed in this week at a series of briefings on what to expect from at the upcoming event. Geneva Solution’s Pokuaa Oduro Bonsrah reports: The […] Continue reading -> Sustainable COVAX Vaccine Funding & Voluntary Manufacturing Licenses are Better Solutions than IP Waiver, Says IFPMA Head 16/05/2021 Elaine Ruth Fletcher In preparation for the next pandemic, the COVAX global vaccine facility “needs a pot of money, where they can be early movers” in competing for, and securing, vaccine doses. That could help scenarios like the ones seen recently, in which rich countries cornered the market on the first available COVID-19 vaccines, leading to severe shortages […] Continue reading -> Sweeping Report on COVID Pandemic: Broken Global Emergency Alert System, Hesitant WHO & Patchy Country Responses 12/05/2021 Elaine Ruth Fletcher A sweeping report on the global pandemic response has found that the World Health Organization should have taken a more “precautionary’ approach to the emerging SARS-COV2 virus in the early days of the pandemic, advising countries earlier on that it could be transmitted person-to-person — rather than only warning of such a “possibility”. The report […] Continue reading -> The ‘Patent Bargain’, Public Good & COVID19 26/04/2021 Priti Patniak/Geneva Health Files As the hotly contested proposal for an IP waiver on COVID-related health products comes up again for debate on Friday, 30 April at the World Trade Organization’s TRIPS Council, legal expert Hyo Yoon Kang looks at the foundations of IP law to challenge “TRIPS waiver” naysayers. Geneva Health Files [GHF]: You have argued that IP […] Continue reading -> Pharma Execs: Unlock Export & Supply Chain Barriers & Ramp Up Sharing Of Excess Vaccine Doses To Beat Back COVID Pandemic 23/04/2021 Elaine Ruth Fletcher A group of leading pharmaceutical industry executives called upon global health leaders to work together to unlock export barriers, open up supply chain bottlenecks, and encourage high-income countries that are hoarding vaccines to redirect their excess doses to the WHO co-sponsored COVAX global vaccine facility – as ways to rapidly scale up equitable vaccine access […] Continue reading -> Damage To Millions Of J&J COVID Vaccines At US Production Plant Could Delay Deliveries, While US Heads Into Fourth Wave 02/04/2021 Madeleine Hoecklin A mix-up with vaccine ingredients at a production site in Baltimore, Maryland, which is manufacturing both the Johnson & Johnson and AstraZeneca COVID-19 vaccines, has led to the contamination of 15 million J&J doses, which risks delaying national and global deliveries of the recently-approved vaccine. The pharma company, which is producing the world’s first single […] Continue reading -> Views from a vaccine manufacturer: Q&A – Abdul Muktadir, Incepta Pharmaceuticals 01/04/2021 Priti Patnaik The debate around technology transfer is proving to be critical in addressing shortages in the production of vaccines. We wanted to know from developing country manufacturers on the challenges they face in making vaccines for COVID-19. Geneva Health Files brings you an interview with Abdul Muktadir, Chairman and Managing Director of the Dhaka-based company Incepta […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
China Sidesteps COVAX Vaccine Donations; Africa Highlights Pandemic Fallout on Health Systems & Societies 27/05/2021 Paul Adepoju China told the World Health Assembly on Wednesday it will continue to support developing countries’ access to affordable COVID-19 vaccines – but it stopped short of any commitment to supplying its recently-approved Sinopharm vaccine to the WHO co-sponsored Global COVAX vaccine facility. WHO officials had said they hoped China would join the COVAX facility, following […] Continue reading -> Gavi Makes Deal With J&J on COVID-19 Vaccines; WHO Says COVID-19 Deaths Could Be 2-3 Times Higher Than 3.2 Million Reported 21/05/2021 Kerry Cullinan Johnson & Johnson will supply COVAX 200 million of its single-dose COVID-19 vaccines by the end of the year, according to a statement on Friday by Gavi, the Vaccine Alliance, announcing the advance purchase agreement. The vaccine will be available to both COVAX members who buy their own vaccines and the COVAX AMC members. “Today’s […] Continue reading -> Pandemic Treaty & Other New COVID Initiatives Grab Center Stage At World Health Assembly 20/05/2021 Pokuaa Oduro-Bonsrah Conquering the COVID-19 pandemic will inevitably be the main topic for discussion at the impending 74th session of the World Health Assembly, which begins Monday, 24 May. Global health experts weighed in this week at a series of briefings on what to expect from at the upcoming event. Geneva Solution’s Pokuaa Oduro Bonsrah reports: The […] Continue reading -> Sustainable COVAX Vaccine Funding & Voluntary Manufacturing Licenses are Better Solutions than IP Waiver, Says IFPMA Head 16/05/2021 Elaine Ruth Fletcher In preparation for the next pandemic, the COVAX global vaccine facility “needs a pot of money, where they can be early movers” in competing for, and securing, vaccine doses. That could help scenarios like the ones seen recently, in which rich countries cornered the market on the first available COVID-19 vaccines, leading to severe shortages […] Continue reading -> Sweeping Report on COVID Pandemic: Broken Global Emergency Alert System, Hesitant WHO & Patchy Country Responses 12/05/2021 Elaine Ruth Fletcher A sweeping report on the global pandemic response has found that the World Health Organization should have taken a more “precautionary’ approach to the emerging SARS-COV2 virus in the early days of the pandemic, advising countries earlier on that it could be transmitted person-to-person — rather than only warning of such a “possibility”. The report […] Continue reading -> The ‘Patent Bargain’, Public Good & COVID19 26/04/2021 Priti Patniak/Geneva Health Files As the hotly contested proposal for an IP waiver on COVID-related health products comes up again for debate on Friday, 30 April at the World Trade Organization’s TRIPS Council, legal expert Hyo Yoon Kang looks at the foundations of IP law to challenge “TRIPS waiver” naysayers. Geneva Health Files [GHF]: You have argued that IP […] Continue reading -> Pharma Execs: Unlock Export & Supply Chain Barriers & Ramp Up Sharing Of Excess Vaccine Doses To Beat Back COVID Pandemic 23/04/2021 Elaine Ruth Fletcher A group of leading pharmaceutical industry executives called upon global health leaders to work together to unlock export barriers, open up supply chain bottlenecks, and encourage high-income countries that are hoarding vaccines to redirect their excess doses to the WHO co-sponsored COVAX global vaccine facility – as ways to rapidly scale up equitable vaccine access […] Continue reading -> Damage To Millions Of J&J COVID Vaccines At US Production Plant Could Delay Deliveries, While US Heads Into Fourth Wave 02/04/2021 Madeleine Hoecklin A mix-up with vaccine ingredients at a production site in Baltimore, Maryland, which is manufacturing both the Johnson & Johnson and AstraZeneca COVID-19 vaccines, has led to the contamination of 15 million J&J doses, which risks delaying national and global deliveries of the recently-approved vaccine. The pharma company, which is producing the world’s first single […] Continue reading -> Views from a vaccine manufacturer: Q&A – Abdul Muktadir, Incepta Pharmaceuticals 01/04/2021 Priti Patnaik The debate around technology transfer is proving to be critical in addressing shortages in the production of vaccines. We wanted to know from developing country manufacturers on the challenges they face in making vaccines for COVID-19. Geneva Health Files brings you an interview with Abdul Muktadir, Chairman and Managing Director of the Dhaka-based company Incepta […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Gavi Makes Deal With J&J on COVID-19 Vaccines; WHO Says COVID-19 Deaths Could Be 2-3 Times Higher Than 3.2 Million Reported 21/05/2021 Kerry Cullinan Johnson & Johnson will supply COVAX 200 million of its single-dose COVID-19 vaccines by the end of the year, according to a statement on Friday by Gavi, the Vaccine Alliance, announcing the advance purchase agreement. The vaccine will be available to both COVAX members who buy their own vaccines and the COVAX AMC members. “Today’s […] Continue reading -> Pandemic Treaty & Other New COVID Initiatives Grab Center Stage At World Health Assembly 20/05/2021 Pokuaa Oduro-Bonsrah Conquering the COVID-19 pandemic will inevitably be the main topic for discussion at the impending 74th session of the World Health Assembly, which begins Monday, 24 May. Global health experts weighed in this week at a series of briefings on what to expect from at the upcoming event. Geneva Solution’s Pokuaa Oduro Bonsrah reports: The […] Continue reading -> Sustainable COVAX Vaccine Funding & Voluntary Manufacturing Licenses are Better Solutions than IP Waiver, Says IFPMA Head 16/05/2021 Elaine Ruth Fletcher In preparation for the next pandemic, the COVAX global vaccine facility “needs a pot of money, where they can be early movers” in competing for, and securing, vaccine doses. That could help scenarios like the ones seen recently, in which rich countries cornered the market on the first available COVID-19 vaccines, leading to severe shortages […] Continue reading -> Sweeping Report on COVID Pandemic: Broken Global Emergency Alert System, Hesitant WHO & Patchy Country Responses 12/05/2021 Elaine Ruth Fletcher A sweeping report on the global pandemic response has found that the World Health Organization should have taken a more “precautionary’ approach to the emerging SARS-COV2 virus in the early days of the pandemic, advising countries earlier on that it could be transmitted person-to-person — rather than only warning of such a “possibility”. The report […] Continue reading -> The ‘Patent Bargain’, Public Good & COVID19 26/04/2021 Priti Patniak/Geneva Health Files As the hotly contested proposal for an IP waiver on COVID-related health products comes up again for debate on Friday, 30 April at the World Trade Organization’s TRIPS Council, legal expert Hyo Yoon Kang looks at the foundations of IP law to challenge “TRIPS waiver” naysayers. Geneva Health Files [GHF]: You have argued that IP […] Continue reading -> Pharma Execs: Unlock Export & Supply Chain Barriers & Ramp Up Sharing Of Excess Vaccine Doses To Beat Back COVID Pandemic 23/04/2021 Elaine Ruth Fletcher A group of leading pharmaceutical industry executives called upon global health leaders to work together to unlock export barriers, open up supply chain bottlenecks, and encourage high-income countries that are hoarding vaccines to redirect their excess doses to the WHO co-sponsored COVAX global vaccine facility – as ways to rapidly scale up equitable vaccine access […] Continue reading -> Damage To Millions Of J&J COVID Vaccines At US Production Plant Could Delay Deliveries, While US Heads Into Fourth Wave 02/04/2021 Madeleine Hoecklin A mix-up with vaccine ingredients at a production site in Baltimore, Maryland, which is manufacturing both the Johnson & Johnson and AstraZeneca COVID-19 vaccines, has led to the contamination of 15 million J&J doses, which risks delaying national and global deliveries of the recently-approved vaccine. The pharma company, which is producing the world’s first single […] Continue reading -> Views from a vaccine manufacturer: Q&A – Abdul Muktadir, Incepta Pharmaceuticals 01/04/2021 Priti Patnaik The debate around technology transfer is proving to be critical in addressing shortages in the production of vaccines. We wanted to know from developing country manufacturers on the challenges they face in making vaccines for COVID-19. Geneva Health Files brings you an interview with Abdul Muktadir, Chairman and Managing Director of the Dhaka-based company Incepta […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Pandemic Treaty & Other New COVID Initiatives Grab Center Stage At World Health Assembly 20/05/2021 Pokuaa Oduro-Bonsrah Conquering the COVID-19 pandemic will inevitably be the main topic for discussion at the impending 74th session of the World Health Assembly, which begins Monday, 24 May. Global health experts weighed in this week at a series of briefings on what to expect from at the upcoming event. Geneva Solution’s Pokuaa Oduro Bonsrah reports: The […] Continue reading -> Sustainable COVAX Vaccine Funding & Voluntary Manufacturing Licenses are Better Solutions than IP Waiver, Says IFPMA Head 16/05/2021 Elaine Ruth Fletcher In preparation for the next pandemic, the COVAX global vaccine facility “needs a pot of money, where they can be early movers” in competing for, and securing, vaccine doses. That could help scenarios like the ones seen recently, in which rich countries cornered the market on the first available COVID-19 vaccines, leading to severe shortages […] Continue reading -> Sweeping Report on COVID Pandemic: Broken Global Emergency Alert System, Hesitant WHO & Patchy Country Responses 12/05/2021 Elaine Ruth Fletcher A sweeping report on the global pandemic response has found that the World Health Organization should have taken a more “precautionary’ approach to the emerging SARS-COV2 virus in the early days of the pandemic, advising countries earlier on that it could be transmitted person-to-person — rather than only warning of such a “possibility”. The report […] Continue reading -> The ‘Patent Bargain’, Public Good & COVID19 26/04/2021 Priti Patniak/Geneva Health Files As the hotly contested proposal for an IP waiver on COVID-related health products comes up again for debate on Friday, 30 April at the World Trade Organization’s TRIPS Council, legal expert Hyo Yoon Kang looks at the foundations of IP law to challenge “TRIPS waiver” naysayers. Geneva Health Files [GHF]: You have argued that IP […] Continue reading -> Pharma Execs: Unlock Export & Supply Chain Barriers & Ramp Up Sharing Of Excess Vaccine Doses To Beat Back COVID Pandemic 23/04/2021 Elaine Ruth Fletcher A group of leading pharmaceutical industry executives called upon global health leaders to work together to unlock export barriers, open up supply chain bottlenecks, and encourage high-income countries that are hoarding vaccines to redirect their excess doses to the WHO co-sponsored COVAX global vaccine facility – as ways to rapidly scale up equitable vaccine access […] Continue reading -> Damage To Millions Of J&J COVID Vaccines At US Production Plant Could Delay Deliveries, While US Heads Into Fourth Wave 02/04/2021 Madeleine Hoecklin A mix-up with vaccine ingredients at a production site in Baltimore, Maryland, which is manufacturing both the Johnson & Johnson and AstraZeneca COVID-19 vaccines, has led to the contamination of 15 million J&J doses, which risks delaying national and global deliveries of the recently-approved vaccine. The pharma company, which is producing the world’s first single […] Continue reading -> Views from a vaccine manufacturer: Q&A – Abdul Muktadir, Incepta Pharmaceuticals 01/04/2021 Priti Patnaik The debate around technology transfer is proving to be critical in addressing shortages in the production of vaccines. We wanted to know from developing country manufacturers on the challenges they face in making vaccines for COVID-19. Geneva Health Files brings you an interview with Abdul Muktadir, Chairman and Managing Director of the Dhaka-based company Incepta […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Sustainable COVAX Vaccine Funding & Voluntary Manufacturing Licenses are Better Solutions than IP Waiver, Says IFPMA Head 16/05/2021 Elaine Ruth Fletcher In preparation for the next pandemic, the COVAX global vaccine facility “needs a pot of money, where they can be early movers” in competing for, and securing, vaccine doses. That could help scenarios like the ones seen recently, in which rich countries cornered the market on the first available COVID-19 vaccines, leading to severe shortages […] Continue reading -> Sweeping Report on COVID Pandemic: Broken Global Emergency Alert System, Hesitant WHO & Patchy Country Responses 12/05/2021 Elaine Ruth Fletcher A sweeping report on the global pandemic response has found that the World Health Organization should have taken a more “precautionary’ approach to the emerging SARS-COV2 virus in the early days of the pandemic, advising countries earlier on that it could be transmitted person-to-person — rather than only warning of such a “possibility”. The report […] Continue reading -> The ‘Patent Bargain’, Public Good & COVID19 26/04/2021 Priti Patniak/Geneva Health Files As the hotly contested proposal for an IP waiver on COVID-related health products comes up again for debate on Friday, 30 April at the World Trade Organization’s TRIPS Council, legal expert Hyo Yoon Kang looks at the foundations of IP law to challenge “TRIPS waiver” naysayers. Geneva Health Files [GHF]: You have argued that IP […] Continue reading -> Pharma Execs: Unlock Export & Supply Chain Barriers & Ramp Up Sharing Of Excess Vaccine Doses To Beat Back COVID Pandemic 23/04/2021 Elaine Ruth Fletcher A group of leading pharmaceutical industry executives called upon global health leaders to work together to unlock export barriers, open up supply chain bottlenecks, and encourage high-income countries that are hoarding vaccines to redirect their excess doses to the WHO co-sponsored COVAX global vaccine facility – as ways to rapidly scale up equitable vaccine access […] Continue reading -> Damage To Millions Of J&J COVID Vaccines At US Production Plant Could Delay Deliveries, While US Heads Into Fourth Wave 02/04/2021 Madeleine Hoecklin A mix-up with vaccine ingredients at a production site in Baltimore, Maryland, which is manufacturing both the Johnson & Johnson and AstraZeneca COVID-19 vaccines, has led to the contamination of 15 million J&J doses, which risks delaying national and global deliveries of the recently-approved vaccine. The pharma company, which is producing the world’s first single […] Continue reading -> Views from a vaccine manufacturer: Q&A – Abdul Muktadir, Incepta Pharmaceuticals 01/04/2021 Priti Patnaik The debate around technology transfer is proving to be critical in addressing shortages in the production of vaccines. We wanted to know from developing country manufacturers on the challenges they face in making vaccines for COVID-19. Geneva Health Files brings you an interview with Abdul Muktadir, Chairman and Managing Director of the Dhaka-based company Incepta […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Sweeping Report on COVID Pandemic: Broken Global Emergency Alert System, Hesitant WHO & Patchy Country Responses 12/05/2021 Elaine Ruth Fletcher A sweeping report on the global pandemic response has found that the World Health Organization should have taken a more “precautionary’ approach to the emerging SARS-COV2 virus in the early days of the pandemic, advising countries earlier on that it could be transmitted person-to-person — rather than only warning of such a “possibility”. The report […] Continue reading -> The ‘Patent Bargain’, Public Good & COVID19 26/04/2021 Priti Patniak/Geneva Health Files As the hotly contested proposal for an IP waiver on COVID-related health products comes up again for debate on Friday, 30 April at the World Trade Organization’s TRIPS Council, legal expert Hyo Yoon Kang looks at the foundations of IP law to challenge “TRIPS waiver” naysayers. Geneva Health Files [GHF]: You have argued that IP […] Continue reading -> Pharma Execs: Unlock Export & Supply Chain Barriers & Ramp Up Sharing Of Excess Vaccine Doses To Beat Back COVID Pandemic 23/04/2021 Elaine Ruth Fletcher A group of leading pharmaceutical industry executives called upon global health leaders to work together to unlock export barriers, open up supply chain bottlenecks, and encourage high-income countries that are hoarding vaccines to redirect their excess doses to the WHO co-sponsored COVAX global vaccine facility – as ways to rapidly scale up equitable vaccine access […] Continue reading -> Damage To Millions Of J&J COVID Vaccines At US Production Plant Could Delay Deliveries, While US Heads Into Fourth Wave 02/04/2021 Madeleine Hoecklin A mix-up with vaccine ingredients at a production site in Baltimore, Maryland, which is manufacturing both the Johnson & Johnson and AstraZeneca COVID-19 vaccines, has led to the contamination of 15 million J&J doses, which risks delaying national and global deliveries of the recently-approved vaccine. The pharma company, which is producing the world’s first single […] Continue reading -> Views from a vaccine manufacturer: Q&A – Abdul Muktadir, Incepta Pharmaceuticals 01/04/2021 Priti Patnaik The debate around technology transfer is proving to be critical in addressing shortages in the production of vaccines. We wanted to know from developing country manufacturers on the challenges they face in making vaccines for COVID-19. Geneva Health Files brings you an interview with Abdul Muktadir, Chairman and Managing Director of the Dhaka-based company Incepta […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
The ‘Patent Bargain’, Public Good & COVID19 26/04/2021 Priti Patniak/Geneva Health Files As the hotly contested proposal for an IP waiver on COVID-related health products comes up again for debate on Friday, 30 April at the World Trade Organization’s TRIPS Council, legal expert Hyo Yoon Kang looks at the foundations of IP law to challenge “TRIPS waiver” naysayers. Geneva Health Files [GHF]: You have argued that IP […] Continue reading -> Pharma Execs: Unlock Export & Supply Chain Barriers & Ramp Up Sharing Of Excess Vaccine Doses To Beat Back COVID Pandemic 23/04/2021 Elaine Ruth Fletcher A group of leading pharmaceutical industry executives called upon global health leaders to work together to unlock export barriers, open up supply chain bottlenecks, and encourage high-income countries that are hoarding vaccines to redirect their excess doses to the WHO co-sponsored COVAX global vaccine facility – as ways to rapidly scale up equitable vaccine access […] Continue reading -> Damage To Millions Of J&J COVID Vaccines At US Production Plant Could Delay Deliveries, While US Heads Into Fourth Wave 02/04/2021 Madeleine Hoecklin A mix-up with vaccine ingredients at a production site in Baltimore, Maryland, which is manufacturing both the Johnson & Johnson and AstraZeneca COVID-19 vaccines, has led to the contamination of 15 million J&J doses, which risks delaying national and global deliveries of the recently-approved vaccine. The pharma company, which is producing the world’s first single […] Continue reading -> Views from a vaccine manufacturer: Q&A – Abdul Muktadir, Incepta Pharmaceuticals 01/04/2021 Priti Patnaik The debate around technology transfer is proving to be critical in addressing shortages in the production of vaccines. We wanted to know from developing country manufacturers on the challenges they face in making vaccines for COVID-19. Geneva Health Files brings you an interview with Abdul Muktadir, Chairman and Managing Director of the Dhaka-based company Incepta […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Pharma Execs: Unlock Export & Supply Chain Barriers & Ramp Up Sharing Of Excess Vaccine Doses To Beat Back COVID Pandemic 23/04/2021 Elaine Ruth Fletcher A group of leading pharmaceutical industry executives called upon global health leaders to work together to unlock export barriers, open up supply chain bottlenecks, and encourage high-income countries that are hoarding vaccines to redirect their excess doses to the WHO co-sponsored COVAX global vaccine facility – as ways to rapidly scale up equitable vaccine access […] Continue reading -> Damage To Millions Of J&J COVID Vaccines At US Production Plant Could Delay Deliveries, While US Heads Into Fourth Wave 02/04/2021 Madeleine Hoecklin A mix-up with vaccine ingredients at a production site in Baltimore, Maryland, which is manufacturing both the Johnson & Johnson and AstraZeneca COVID-19 vaccines, has led to the contamination of 15 million J&J doses, which risks delaying national and global deliveries of the recently-approved vaccine. The pharma company, which is producing the world’s first single […] Continue reading -> Views from a vaccine manufacturer: Q&A – Abdul Muktadir, Incepta Pharmaceuticals 01/04/2021 Priti Patnaik The debate around technology transfer is proving to be critical in addressing shortages in the production of vaccines. We wanted to know from developing country manufacturers on the challenges they face in making vaccines for COVID-19. Geneva Health Files brings you an interview with Abdul Muktadir, Chairman and Managing Director of the Dhaka-based company Incepta […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Damage To Millions Of J&J COVID Vaccines At US Production Plant Could Delay Deliveries, While US Heads Into Fourth Wave 02/04/2021 Madeleine Hoecklin A mix-up with vaccine ingredients at a production site in Baltimore, Maryland, which is manufacturing both the Johnson & Johnson and AstraZeneca COVID-19 vaccines, has led to the contamination of 15 million J&J doses, which risks delaying national and global deliveries of the recently-approved vaccine. The pharma company, which is producing the world’s first single […] Continue reading -> Views from a vaccine manufacturer: Q&A – Abdul Muktadir, Incepta Pharmaceuticals 01/04/2021 Priti Patnaik The debate around technology transfer is proving to be critical in addressing shortages in the production of vaccines. We wanted to know from developing country manufacturers on the challenges they face in making vaccines for COVID-19. Geneva Health Files brings you an interview with Abdul Muktadir, Chairman and Managing Director of the Dhaka-based company Incepta […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Views from a vaccine manufacturer: Q&A – Abdul Muktadir, Incepta Pharmaceuticals 01/04/2021 Priti Patnaik The debate around technology transfer is proving to be critical in addressing shortages in the production of vaccines. We wanted to know from developing country manufacturers on the challenges they face in making vaccines for COVID-19. Geneva Health Files brings you an interview with Abdul Muktadir, Chairman and Managing Director of the Dhaka-based company Incepta […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy